INTRODUCTION
Breakthrough pain is prevalent (41-95%) among patients with cancer [1, 2] and presents challenges to effective pain management [2, 3] . Breakthrough pain typically exhibits a rapid onset (typically \5 min, ranging from 1 s to 30 min until peak intensity), severe intensity, and lasts for\1 h, but may last for up to 1 to 2 h [4, 5] . Therefore, optimal relief from breakthrough pain is best attained by administering analgesics which have pharmacokinetics and pharmacodynamics that closely match the time course of breakthrough pain events.
The transmucosal route of administration of analgesics can avoid first-pass hepatic metabolism and allow rapid entry of drugs into the systemic circulation [6, 7] . It can also yield increased bioavailability relative to orally administered drugs [8] . Current clinical guidelines recommend transmucosal fentanyl as an option for the relief of breakthrough cancer pain [9] . A variety of transmucosal fentanyl products with different routes of administration (e.g., lozenge, buccal tablet, buccal film, sublingual tablet, sublingual spray, and nasal spray) are available. A novel sublingual tablet form of fentanyl (Abstral Ò ;
Galena Biopharma, Portland, OR, USA) was developed that would undergo rapid disintegration and absorption within the time of onset and duration of breakthrough pain [10] .
The subjective nature of pain is reflected in the highly variable and individualized responses to pain therapies. Patient perception of ''dwell time'' contributes to preference, which in turn can affect compliance rates [11] .
Previous studies have demonstrated the efficacy of sublingual fentanyl tablets in the treatment of breakthrough pain in patients who are opioid tolerant [12, 13] . Preliminary assessments of the disintegration time and patient acceptability of this fentanyl formulation have been previously presented [14] [15] [16] . Here, we present a detailed assessment of patient perception of the complete disintegration time of sublingual fentanyl tablets in practice-based, opioid-tolerant patients. Measurement of pain relief was not an objective of this study.
METHODS

Study Population
Men and women aged 18-75 years with chronic pain who were tolerant to opioids (i.e., morphine 60 mg/day or equivalent for C1 week) were eligible for enrollment in the study. Women of child-bearing potential had to be using an acceptable form of birth control to participate in the study. Exclusion criteria included: allergy to fentanyl or its derivatives; history of severe chronic obstructive pulmonary disease; or asthma that, in the investigator's opinion, was medically significant. Pregnant or lactating women and patients deemed by the investigator to be medically unstable were also excluded from the study. 
Study Design
Statistical Methods
Descriptive statistics were used to summarize pooled data from the individual treatment groups. Analyses were performed using Prism v5.04 (GraphPad Software, Inc., La Jolla, CA, USA). One-way analysis of variance (ANOVA), followed by the Bonferroni post hoc test, was used to compare the total disintegration times among the groups administered the 3 strengths of sublingual fentanyl. A 2-tailed unpaired t test was used to assess the difference in disintegration time between men and women across all doses of sublingual fentanyl. Linear regression analysis was used to assess the effects of age on disintegration time across all doses of sublingual fentanyl.
RESULTS
Demographics
Pooled baseline demographics of patients in all treatment groups are summarized in Table 1 .
The mean age for all patients in this study was Table 2 .
Disintegration Time of Sublingual Fentanyl
The disintegration time (mean ± SD) for the sublingual placebo used during training was 107.1 ± 73.4 s. The disintegration time for sublingual fentanyl across all doses was 88.2 ± 55.1 s; there was a non-significant trend toward longer disintegration times for the 200 lg (96.7 ± 57.9 s) and 300 lg (98.6 ± 64.8 s) sublingual fentanyl doses compared with the 100 lg sublingual fentanyl dose (69.5 ± 40.5 s; Fig. 1 ). Disintegration time for sublingual fentanyl across all doses was similar between men and women (Fig. 2) , and was not affected by age (Fig. 3) . No AEs occurred during the study.
DISCUSSION
The persistently high prevalence of breakthrough pain in patients with cancer indicates an ongoing need for rapidly acting analgesics with pharmacokinetic properties that match the rapid onset and short duration of breakthrough pain [21, 22] Hydrocodone and acetaminophen 2 (7)
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Buprenorphine transdermal system 1 lg dose group to 98.6 s in the 300 lg dose group. Although there were no significant differences in disintegration time between sublingual fentanyl dose groups, this study was not powered for statistical analysis. The mean disintegration time across all doses of sublingual fentanyl did not differ significantly by age or sex. Patients in this study were exposed to placebo tablet training prior to sublingual fentanyl administration. Using a sublingual placebo tablet to familiarize patients with optimal placement of the drug and perception of its complete disintegration may be a useful component of individualized care in the management of breakthrough cancer pain [25] .
Effective treatment of breakthrough cancer pain may be influenced by patient acceptance of the drug, and it is important to note that the present study focused on disintegration time and not pain relief. In addition, the open-label, nonrandomized design of this study limits the conclusions that can be drawn. Furthermore, the study did not include crossover to a comparator treatment such as a matching placebo sublingual tablet or a different transmucosal fentanyl product. Finally, the small sample size of this study may not have provided adequate statistical power to detect differences between groups. Therefore, additional studies are needed to assess the degree to which disintegration time is of practical importance in the willingness of patients to switch from their current treatment to sublingual fentanyl. 
CONCLUSIONS
